NVS stock news · Novartis AG
Get alerts for NVS
Follow Novartis AG (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVSDeutsche Bank changed its rating for Novartis from 'Hold' to 'Sell'.
Bad for NVSDeutsche Bank cut its Novartis rating from Hold to Sell. That is negative for the stock, but the report gives no new reason tied to the company's business.
A federal court will let a lawsuit against Novartis move forward instead of throwing it out.
Bad for NVSA judge let a lawsuit against Novartis move toward discovery and possible trial, raising its legal risk. The accusations remain unproven.
Novartis Canada got a thumbs up from INESSS to help pay for Kisqali for breast cancer patients.
Good for NVSNovartis received a positive recommendation for public coverage of Kisqali for some high-risk breast cancer patients. This supports wider access, though public payers still need to act.
The FDA has approved Novartis's Rhapsido, making it the first medicine for chronic friction hives.
Good for NVSNovartis received U.S. approval for Rhapsido to treat chronic friction hives. The trial results and new treatment option make this favorable, though the approved group is limited.
Novartis stopped testing its ALS drug but bought a brain delivery system from Sironax for $1.
NeutralNovartis stopped an ALS trial and acquired a brain-delivery platform; the bad and good parts offset, so the company’s outlook is unchanged today.
A major investor is pushing Novartis to improve how it handles buying other companies after recent problems.
Bad for NVSNovartis faces investor pressure after two Phase 3 failures and contested deals; governance changes and financial scrutiny are likely to increase.
Sarepta Therapeutics shares drop after a competitor's trial results disappoint.
Bad for NVSNovartis’ Phase 3 HARBOR study did not meet its primary endpoint for DM1, which is a setback for the program.
Stocks fell today as oil prices hit $98, raising worries about inflation.
Bad for NVSNovartis disclosed that pelacarsen failed a pivotal Phase 3 cardiovascular outcomes trial, which is a setback for that program.
Why did Amgen's stock drop on Tuesday?
Bad for NVSNovartis reported that its Phase 3 Lp(a) drug failed to meet the trial's primary endpoint, which weakens prospects for that program.
Eli Lilly's stock dropped on Tuesday. What's going on?
Bad for NVSNovartis shares plunged after a Phase 3 HARBOR trial for del-desiran failed to meet its primary endpoint, pressuring the company.
Novartis, Ionis Pharmaceuticals, and other major stocks dropped in early trading on Tuesday.
Bad for NVSNovartis shares fell sharply in pre-market trading after the company announced that its pelacarsen phase III Lp(a) HORIZON trial did not meet its primary endpoint, leading to a significant drop in its stock price. Ionis Pharmaceuticals also saw a decline in its shares due to the news.
Keep an eye on United Natural Foods, ABM Industries, and 3 other stocks as Tuesday approaches.
Bad for NVSNovartis reported that the pelacarsen phase III Lp(a) HORIZON trial missed its primary endpoint, which is a setback for that drug program and lowered the stock.
Keep an eye on United Natural Foods, ABM Industries, and 3 other stocks this Tuesday.
Bad for NVSNovartis disclosed that the pelacarsen phase III trial missed its main goal, and the stock fell in after-hours trading; that removes expected results from this program and hurt sentiment.
Following the identification of a trial halt by a Wall Street analyst, reports emerged regarding three fatalities.
Bad for NVSNovartis suspended rap-cel trials after three patient deaths, creating acute safety, regulatory, and reputational damage for its cell‑therapy program.
Analyst suggests Enliven's leading medication may transform the leukemia treatment landscape.
Bad for NVSPotential competitive threat from Enliven's ELVN-001 could impact Novartis' market position in CML treatments.